Jump to content
  • rrdiLogo384x64.jpg

    We are rosaceans and this is a grassroots rosacea non profit organization. Finding the Cure for rosacea. If you like to read, scroll down to the bottom. If you prefer videos, scroll down to view all the videos about the RRDi. What's with the butterfly? We need 100 Active Subscribers! To learn more about the RRDi watch the videos by scrolling below, or if you prefer reading, keep scrolling. If you want to change how the RRDi is run, why not volunteer to post (subscription fees waived for volunteers) and tell us what you think the RRDi should be doing. 

    Join the most private rosacea community on the web!

    Videos & RRDi Social Media Accounts

  • Forum Statistics

    • Total Topics
      6.5k
    • Total Posts
      8.3k
  • The Rosacea Research & Development Institute [RRDi] is the first 501 (c) (3) non profit organization approved by the IRS established June 7, 2004 in the State of Hawaii, USA for the purpose of finding a cure for rosacea, researching rosacea, and to form a rosacea patient advocacy organization established by volunteer rosaceans for rosacea sufferers. In December 2019 we have moved the corporate office to the State of Alabama and have registered as a non profit corporation.

    Our non profit organization for rosacea patient advocacy web site is a digital data repository of rosacea information that can serve you personally as an armamentarium of rosacea treatment options. We have tools to help you in your search for a cure to rosacea, or at least a way to control it.

    We have chosen the Invision Community as the chief digital platform tool (with beta versions for Android and iOS mobile apps) to use, a public platform for guests and inactive members. Our member forum is the most private forum for rosacea on the internet. We also have a private platform using Tapatalk using our rosacea-control.com domain. 

    We are rosacea sufferers [rosaceans] and all are volunteers. We rely on donations. No one is receiving a salary or getting paid. We don't spend donated funds on private contractors that are owned by any member of the board of directors. We do not spend donated funds so our members can attend dermatology conventions. All donations are spent on keeping this non profit organization for rosacea sufferers a viable patient advocacy organization and our rules state that 'members may not profit from the institute' (rule number 3). Read our mission statement

    No one has a paid salary, we pay NO private contractors nor do we use donations so our members can attend dermatology conventions. 

    All the other rosacea non profits are not run by rosacea sufferers (see Other Non Profit Rosacea Organizations on this page). Check out the other non profit organizations for rosacea, discover for yourself and you will find out who serve on the board of directors (non rosaceans - dermatologists/businessmen) and then simply follow the money (what does the organization spend most of the donated money on?) and discover for yourself that the other non profit organizations for rosacea spend most of the donations on (1) private contractors, (2) dermatologist member conventions or (3) salaries. We have no special interest other than finding the cure for rosacea and forming a rosacea patient advocacy organization. Our non profit has no salaries, no spending on private contractors, no expenses for member conventions. Follow the money (this is where we spend our money). Notice where most of the money is spent with another rosacea non profit, who has spent millions of dollars on private contractors owned by the president of the non profit and only 10% on rosacea research. 

    Read our Misson Statement and see if you agree? If you suffer from rosacea, this is the rosacea non profit to join. Your membership increases our impact on the medical community. Our goal is to reach 10,000 members. Please join and help us reach our goal. What if 10,000 members got together and each donated one dollar and all the members agreed we should sponsor a certain rosacea research study. Is this possible? Only with your help. 

    You may want to read our post about Anonymity, Transparency and Posting before joining. We have now switched to a subscription member service

    The logo of the RRDi includes a butterfly because rosacea typically manifests itself in a facial butterfly formation, however the irony of the butterfly effect is apropros. Learn More.

    You may want to learn about the history of this non profit or why it was formed

    If you are a rosacean, volunteer by joining our private member forum and posting or in our public guest forum (registration required) becoming a part of 'finding the cure' for rosacea if you join. Our goal is 10,000 members. Membership is free. You can help us reach our goal by joining with just your email address.  if privacy is of paramount importance to you use Sign in with Apple and join our private member forum. Or you can simply browse our web site and guest forum for free. Our non profit affiliate store is another source of rosacea treatment options. 

    If you want to post about your rosacea, we certainly allow you to post feedback in our GUEST forum or register an account in our member forum, i.e,, in our public community support, and, if you want to learn about and treat your rosacea, this is the best non profit organization for rosacea sufferers. At the social networks like Facebook, Instagram or Reddit can you find the incredible digital tools the RRDi provides free to its members or the ability to find what you are searching for in rosacea research? Are you able through such social media groups to influence the medical community how you feel about rosacea? Read our mission statement and compare with your private rosacea social media group, i.e., like Facebook, Instagram or Reddit.  

    The RRDi is registered at GuideStar and Trustpilot • Write a Review of Our Non Profit

  • Member Statistics

    1,679
    Total Members
    499
    Most Online
    dani
    Newest Member
    dani
    Joined


  • Registered with the USA Internal Revenue Service

    IRSlogo.png

    EIN 20-1259275

  • 240px-Seal_of_Alabama.svg.png

  • Alabama Secretary of State Certification

    Entity Identification Number 596-247

  • Guest Signup

    Show your support for the RRDi

  • Posts

    • If we had 100 core members who subscribe a dollar a month we could see the RRDi website and non profit organization going. Would you be one the core 100 members who subscribe a dollar a month? 
    • Ann Dermatol Venereol. 2024 Jun 6;151(3):103244. doi: 10.1016/j.annder.2023.103244. Online ahead of print. NO ABSTRACT PMID:38848643 | DOI:10.1016/j.annder.2023.103244 {url} = URL to article
    • Indian J Dermatol. 2024 Mar-Apr;69(2):152-158. doi: 10.4103/ijd.ijd_815_22. Epub 2024 Apr 29. ABSTRACT Gluten, a polypeptide hapten, found in many cereals such as barley, wheat, rye, oats, and others, has been recently implicated in a range of cutaneous disorders ranging from chronic plaque psoriasis through psoriatic arthritis, urticaria (chronic as well as paediatric onset), and angioedema to lichen planus, vitiligo, and rosacea. The evidence for them is still not well reviewed. To generate evidence for the causal role of gluten in various dermatological disorders. The Pubmed, MedLine, and EMBASE databases were searched using the keywords "Gluten" and one of the dermatoses, namely, "Atopic Dermatitis", "Vasculitis", "Psoriasis", "Psoriatic Arthritis", "Acne", "Alopecia Areata", and "Immunobullous disorders". All articles published in English for which free full text was available were taken into consideration. The search strategy returned in a total of 1487 articles which were screened for relevance and elimination of duplicates. Ultimately, around 114 articles were deemed suitable. The data were extracted and presented in the narrative review format. A simple and cost-effective solution to many of these chronic and lifelong conditions is to restrict gluten in the diet. However, the dermatologist would do well to remember that in the vast majority of dermatological disorders including the ones listed here, gluten restriction is not warranted and can even lead to nutritional deficiencies. The evidence varied from Grade I for some disorders like psoriatic arthritis to Grade IV to most disorders like acne, vitiligo, vasculitis, and atopic dermatitis. Herein, we review the evidence for each of these conditions and make practical recommendations for gluten restriction in them. PMID:38841247 | PMC:PMC11149804 | DOI:10.4103/ijd.ijd_815_22 {url} = URL to article
    • Skin Appendage Disord. 2024 Jun;10(3):207-214. doi: 10.1159/000536246. Epub 2024 Feb 2. ABSTRACT INTRODUCTION: Rosacea is a common chronic inflammatory dermatosis characterized by erythema, telangiectasia, papules, and pustules on the central face. The frequency of contact sensitization complicating rosacea and its therapy is unknown, with only few studies published in the literature. In the present study, we aimed to evaluate contact sensitivity in patients with rosacea. METHODS: A total of 50 rosacea patients and 50 age- and sex-matched healthy controls were enrolled. Both groups were patch tested with the European Baseline Series. RESULTS: A positive reaction to at least one allergen of the European Baseline Series was observed in 15 (30%) of rosacea patients and 10 (20%) of the healthy controls. Although the rate of positive reaction in the rosacea group was higher than in the controls, no statistically significant difference was documented. In addition, the total number of positive reactions to allergens in the rosacea group was higher than the control group, namely, 26 versus 17. CONCLUSION: Contact hypersensitivity may coexist with rosacea. Its identification holds significant clinical relevance, influencing the long-term management and justifying the application of patch testing in rosacea patients. PMID:38835717 | PMC:PMC11147521 | DOI:10.1159/000536246 {url} = URL to article
    • J Cosmet Dermatol. 2024 Jun 3. doi: 10.1111/jocd.16372. Online ahead of print. ABSTRACT BACKGROUND & AIM: Rosacea is a chronic inflammatory, multifactorial disease for which combination therapy could be an effective treatment. In this study, we evaluate the effect of the combination therapy of brimonidine 0.33% and ivermectin 1% as a single cream for the treatment of papulopustular rosacea. METHOD: A stable and appropriate formulation was prepared by adding the aqueous phase to the lipid phase while being stirred. The stability and physicochemical properties of the formulation were evaluated under accelerated conditions. Twelve patients (36-60 years) with mild to moderate papulopustular rosacea and a Demodex count of five or more were treated with the combination of brimonidine 0.33% and ivermectin 1% cream. Clinician's Erythema Assessment (CEA), Patients Self-Assessment (PSA), skin erythema (ΔE) and lightness (ΔL), and skin biophysical parameters including transepidermal water loss (TEWL), skin hydration, pH, and sebum content, as well as erythema and melanin index and ultrasound parameters, were measured before treatment and 4 and 8 weeks after. Adverse drug reactions were also recorded. RESULTS: CEA and PSA decreased significantly from 3 to 2 after 8 weeks, respectively (p-value = 0.014 for CEA and 0.010 for PSA). ΔE and ΔL, as well as skin erythema index and TEWL improved after 8 weeks of treatment (p < 0.05). Two patients withdrew from the study in the first week because of local adverse effects; one developed flushing following treatment and left the investigation after 4 weeks and another patient withdrew from the study after 4 weeks due to deciding to become pregnant. CONCLUSION: Eight-week treatment with the combination of brimonidine 0.33% and ivermectin 1% was shown to be effective for improvement of erythema and inflammatory lesions in mild to moderate papulopustular rosacea. PMID:38831548 | DOI:10.1111/jocd.16372 {url} = URL to article
    • J Cosmet Dermatol. 2024 Jun 3. doi: 10.1111/jocd.16413. Online ahead of print. ABSTRACT OBJECTIVE: To investigate the efficacy and safety of a repairing mask as an adjunctive treatment for skin barrier maintenance of mild to moderate rosacea. METHODS: Patients with rosacea were recruited in this dual center randomized controlled trial from November 2019 to December 2021. A total of 64 patients were included and randomized into two groups at a ratio of 3:1 into a mask group (n = 47) and a control group (n = 17). Patients in the mask group received treatment with Dr. Yu Centella asiatica repairing facial mask three times weekly for a duration of 6 weeks. All participants were instructed to continue their regimen of 50 mg oral minocycline twice daily and to apply Dr. Yu Intensive Hydrating Soft Cream twice daily. The primary endpoint of this study was the Investigator Global Assessment (IGA) score. RESULTS: A total of 54 patients completed this trial, with 41 in the mask group and 13 in the control group. After using this facial mask for 3 and 6 weeks, the IGA, facial skin dryness, facial flushing, and severity of skin lesion in the mask group showed significantly improvement (p < 0.05). Moreover, the change in the delta degree of skin flushing was significantly higher than that in the control group (p = 0.037). Throughout the study, no adverse events were reported in either group of participants. CONCLUSION: The Dr. Yu Centella asiatica repairing facial mask, as an adjunctive treatment of rosacea, appears to effectively repair and protect the skin barrier, alleviate cutaneous symptoms of rosacea, and is both efficacious and safe for patient use. PMID:38831627 | DOI:10.1111/jocd.16413 {url} = URL to article
    • J Drugs Dermatol. 2024 Jun 1;23(6):446-449. doi: 10.36849/JDD.8362. ABSTRACT Acne vulgaris is a common chronic dermatological condition characterized by obstruction and inflammation of pilosebaceous units. Recent research on a different dermatologic condition has demonstrated that the use of vasodilatory medications is associated with a decreased relative risk of rosacea. This finding is significant due to the overlapping inflammatory pathways involved in rosacea and acne. Herein, a retrospective cohort study was designed to determine the correlation between vasodilator usage and the risk of developing acne within 5 years, contrasting it with thiazide diuretics, chosen as a control due to its non-vasodilatory antihypertensive mechanism and availability of data. Angiotensin-converting enzyme (ACE) inhibitors (RR, 0.775; 95% CI, 0.727-0.826; P&lt;0.05), angiotensin receptor blockers (ARBs) (RR, 0.739; 95% CI, 0.685-0.797; P&lt;0.05), beta-blockers (BB) (RR, 0.829; 95% CI, 0.777-0.885; P&lt;0.05), and calcium channel blockers (CCB) usage (RR, 0.821, 95% CI, 0.773-0.873; P&lt;0.05) were associated with a significantly lower risk of developing acne within 5 years of initiating therapy compared to thiazide diuretics. It is unclear if thiazide diuretics are more likely to cause acne within the adult population or if vasodilators are protective against the development of acne. Finding mechanisms and therapeutics that lower the risk of developing acne is of significant public health interest, and this study provides a step toward this endeavor. Further research is required to uncover the underlying mechanisms for this reduction in the development of acne.&nbsp; J Drugs Dermatol. 2024;23(6):446-449.&nbsp; &nbsp;&nbsp; doi:10.36849/JDD.8362. PMID:38834225 | DOI:10.36849/JDD.8362 {url} = URL to article
    • Cont Lens Anterior Eye. 2024 Jun 3:102247. doi: 10.1016/j.clae.2024.102247. Online ahead of print. ABSTRACT PURPOSE: To compare the efficacy of topical autologous serum and platelet-rich plasma (PRP) in patients with severe dry eye and persistent epithelial defects. METHODS: Sixty-seven eyes of 42 patients including 12 Sjogren, 11 meibomian gland dysfunction, 8 post penetrating keratoplasty, 5 acne rosacea, 5 chemical burn and 3 neurotophic keratopathy were analyzed. Best corrected visual acuity, Schirmer, Ocular Surface Disease Index (OSDI), tear break-up time, Oxford staining scores were measured before the treatment and 1 month. One month scores of two groups were compared. RESULTS: Thirty three eyes received autologous serum and 34 received PRP. There was no statistically significant differences between two groups in ocular surface parameters at baseline. Statistically significant improvements were achieved in both groups in all parameters at 1 month (p < 0.05). Schirmer score improved from 7.9 ± 7.6 to 10.6 ± 8.4 mm in autologous serum (p < 0.001) and from 10.9 ± 9.5 to 13.3 ± 10.1 in PRP (p < 0.001); BUT from 4.3 ± 2.7 to 6.7 ± 3.4 s (p < 0.001) and 4.5 ± 3.0 to 6.0 ± 3.6 (p < 0.001); OSDI from 47.7 ± 14.7 to 25.7 ± 11.0 (p < 0.001) and from 54.1 ± 17.3 to 26.8 ± 11.0 (p < 0.001); Oxford score from 4.0 ± 1.0 to 1.3 ± 1.1 in (p < 0.001) and 3.9 ± 0.9 to 1.6 ± 1.3 (p < 0.001) respectively. Significant visual improvement was achieved with PRP from 0.81 ± 0.73 LogMAR to 0.72 ± 0.63 (p = 0.025), whereas insignificant with serum from 0.60 ± 0.65 to 0.57 ± 0.67 (p = 0.147). Mean epithelial healing time was 6.7 ± 4.7 (2-14) days in serum and 3.6 ± 1.9 (2-7) in PRP (p = 0.195). CONCLUSIONS: Both treatments are equally effective in severe dry eye and persistent epithelial defects. Although, visual gain is higher in PRP, autologous serum may be preferable due to low cost. PMID:38834425 | DOI:10.1016/j.clae.2024.102247 {url} = URL to article
    • Lasers Med Sci. 2024 Jun 1;39(1):146. doi: 10.1007/s10103-024-04098-9. ABSTRACT Previous clinical studies have shown that pulsed dye laser (PDL) and intense pulsed light (IPL) are effective for treating erythematotelangiectatic rosacea(ETR). This article aims to compare the efficacy and safety of PDL and IPL at three different wavelength bands (broad-band, single-narrow-band, and dual-narrow-band) in treating ETR. Sixty subjects with ETR were randomly categorized into four groups and received one of the following laser treatments: PDL (595 nm), IPL with Delicate Pulse Light (DPL, 500-600 nm), IPL with M22 590 (590-1200 nm), or IPL with M22 vascular filter (530-650 nm and 900-1200 nm). Four treatment sessions were administered at 4-week intervals, with one follow-up session 4 weeks after the final treatment. The efficacy of the four lasers was evaluated by comparing the clinical symptom score, total effective rate, VISIA red area absolute score, and RosaQoL score before and after treatment. The safety was evaluated by comparing adverse reactions such as pain, purpura, erythematous edema, and blister. All 60 subjects completed the study. Within-group effects showed that the clinical symptom score, VISIA red area absolute score, and RosaQoL score of all four groups were significantly reduced compared to before treatment (p < 0.001). Between-group effects showed no statistically significant difference among the four laser groups. Safety analysis showed that all four lasers were safe, but the incidence of blister was higher in the M22 vascular group. Nonpurpurogenic PDL, DPL, M22 590, and M22 vascular were equally effective in treating ETR and were well-tolerated. ClinicalTrial.gov Identifier: NCT05360251. PMID:38822948 | DOI:10.1007/s10103-024-04098-9 {url} = URL to article
×
×
  • Create New...

Important Information

Terms of Use